Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Farina, Francesca  [Clear All Filters]
2024
Salmanton-García J, Marchesi F, Farina F, Weinbergerova B, Itri F, Dávila-Valls J, Martín-Pérez S, Glenthøj A, Hersby DStampe, da Silva MGomes, et al. Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022. EClinicalMedicine. 2024;71:102553.
Aiello TFrancesco, Salmanton-García J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, Farina F, Dávila-Valls J, Martín-Pérez S, El-Ashwah S, et al. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica. 2024.
Mori G, Diotallevi S, Farina F, Lolatto R, Galli L, Chiurlo M, Acerbis A, Xue E, Clerici D, Mastaglio S, et al. High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies. Microorganisms. 2024;12(1).
Lahmer T, Salmanton-García J, Marchesi F, El-Ashwah S, Nucci M, Besson C, Itri F, Jaksic O, Čolović N, Weinbergerova B, et al. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey. Infection. 2024.
2023
Noviello M, Lorentino F, Xue E, Racca S, Furnari G, Valtolina V, Campodonico E, Dvir R, Lupo-Stanghellini MTeresa, Giglio F, et al. Human herpesvirus 6-specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients. Blood Adv. 2023.
Xue E, Scorpio G, Ruggeri A, Clerici D, Farina F, Campodonico E, Acerbis A, Fiore P, Bruno A, Carrabba MG, et al. Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience. Curr Res Transl Med. 2023;71(3):103402.
Salmanton-García J, Marchesi F, Koehler P, Weinbergerova B, Colović N, Falces-Romero I, Buquicchio C, Farina F, VAN Praet J, Biernat MM, et al. MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY. Int J Antimicrob Agents. 2023:106952.
El-Ashwah S, Salmanton-García J, Bilgin YM, Itri F, Žák P, Weinbergerova B, Verga L, Omrani AS, da Silva MGomes, Szotkowski T, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2023:1-10.
Musto P, Salmanton-García J, Sgherza N, Bergantim R, Farina F, Glenthøj A, Seval GCengiz, Weinbergerova B, Bonuomo V, Bilgin YM, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry. Hematol Oncol. 2023.
Salmanton-García J, Marchesi F, Itri F, Farina F, Hoenigl M, Cordoba R, El-Ashwah S, Busca A, Criscuolo M, Cornely OA, et al. Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients. Hemasphere. 2023;7(11):e970.
2021
Clerici D, Oltolini C, Greco R, Ripa M, Giglio F, Mastaglio S, Lorentino F, Pavesi F, Farina F, Liberatore C, et al. The place in therapy of ceftazidime/avibactam and ceftolozane/tazobactam in hematological patients with febrile neutropenia. Int J Antimicrob Agents. 2021:106335.
Greco R, Lorentino F, Albanese S, Stanghellini MTeresa Lup, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, et al. Post-Transplant Cyclophosphamide and Sirolimus based Graft-versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplant Cell Ther. 2021.
Lupo-Stanghellini MTeresa, Piemontese S, Assanelli A, Serpenti F, Mastaglio S, Clerici D, Giglio F, Greco R, Lorentino F, Pavesi F, et al. Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up. Hemasphere. 2021;5(11):e654.
2014
Tourette C, Farina F, Vazquez-Manrique RP, Orfila A-M, Voisin J, Hernandez S, Offner N, J Parker A, Menet S, Kim J, et al. The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity. PLoS Biol. 2014;12(6):e1001895.